Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | TYMP | P19971 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17700319 | 0.82 | PTPN1 (0.39) | ERN1PDE10APTPN1PTGDR2PTGES | |
| SCHEMBL6103441 | 0.82 | OPRK1 (0.39) | ERN1PTGDR2OPRK1ALDH1A1 | |
| SCHEMBL6103929 | 0.82 | ERN1 (0.44) | ERN1PTGDR2OPRK1ALDH1A1PPARG | |
| SCHEMBL6104216 | 0.81 | OPRK1 (0.46) | PTGDR2OPRK1ALDH1A1 | |
| SCHEMBL6103096 | 0.79 | ERN1 (0.40) | ERN1OPRK1ALDH1A1 | |
| SCHEMBL6104069 | 0.78 | OPRK1 (0.58) | PDE10AOPRK1 | |
| SCHEMBL18064888 | 0.77 | PDE10A (0.41) | PDE10APTPN1OPRK1PTGER4 | |
| SCHEMBL6104617 | 0.76 | CDC7 (0.38) | ERN1PTGDR2OPRK1ALDH1A1LIPG | |
| SCHEMBL2427274 | 0.76 | PIM1 (0.45) | ERN1 | |
| SCHEMBL2427272 | 0.76 | PIM1 (0.45) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160864-A1 | Acrylamide derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1593673-A1 | ACRYLAMIDE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160864-A1 | Acrylamide derivative, process for producing the same, and use | CCR5, MSR1, CCR2 | ERN1 1319/4885PDE10A 3133/4885PTPN1 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.